Modelling of Parkinson's disease in mice

MF Chesselet, F Richter - The Lancet Neurology, 2011 - thelancet.com
MF Chesselet, F Richter
The Lancet Neurology, 2011thelancet.com
Although progress has been made in the symptomatic treatment of Parkinson's disease
since the discovery of L-dopa in the 1960s, no neuroprotective therapy is yet available.
Absence of adequate animal models of the disease that enable prediction of clinical success
of potential treatments is often cited as a major impediment to progress and discourages
researchers and pharmaceutical companies from investing resources to develop such
treatments. Classic models are still widely used, but have been disappointing, and …
Summary
Although progress has been made in the symptomatic treatment of Parkinson's disease since the discovery of L-dopa in the 1960s, no neuroprotective therapy is yet available. Absence of adequate animal models of the disease that enable prediction of clinical success of potential treatments is often cited as a major impediment to progress and discourages researchers and pharmaceutical companies from investing resources to develop such treatments. Classic models are still widely used, but have been disappointing, and development of genetic models has given new hope. However, can a human disease be faithfully reproduced in a mouse? In this Review we summarise evidence that some genetic mouse models do reproduce key features of Parkinson's disease and show that much can be learned from even imperfect models. The hope is that this information could be used to advance the search for neuroprotective therapies for Parkinson's disease.
thelancet.com